Samik Pharm.
Financials
Valuation Metrics
Samik Pharm.'s Market Cap is ₩720B. Ranked #1445 of 2,405 in KR market (top 60%), #821 of 1,627 on KOSDAQ (top 50%), #159 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 69%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 72.03B KRW | KR#1,445/2,405 Sec#159/231 |
| Revenue | 60.02B KRW | KR#1,693/2,405 Sec#114/231 |
| Net Income | -754.9M KRW | KR—/2,405 Sec—/231 |
| Total Assets | 85.22B KRW | KR#1,895/2,405 Sec#153/231 |
| Net Assets | 68.98B KRW | KR#1,691/2,405 Sec#143/231 |
| Value | ||
| P/B | 1.04x | KR#1,568/2,405 Sec#98/231 |
| P/S | 1.20x | KR#1,549/2,405 Sec#89/231 |
| EV/EBITDA | 21.23x | KR#1,072/2,405 Sec#65/231 |
| FCF Yield | -1.87% | KR—/2,405 Sec—/231 |
| Profitability | ||
| ROE | -1.09% | KR#1,627/2,405 Sec#112/231 |
| ROA | -0.89% | KR#1,662/2,405 Sec#115/231 |
| Op. Margin | 5.45% | KR#899/2,405 Sec#66/231 |
| Financial Health | ||
| Debt Ratio | 23.54% | KR#451/2,405 Sec#54/231 |
| Total Debt | 2.68B KRW | KR#1,868/2,405 Sec#181/231 |
| FCF | -1.35B KRW | KR#1,294/2,405 Sec#100/231 |
| Cash | 5.22B KRW | KR#1,979/2,405 Sec#183/231 |
| Current Ratio | 4.85x | KR#294/2,405 Sec#51/231 |
| Net Debt/EBITDA | -0.77x | KR#426/2,405 Sec#24/231 |
| Dividend | ||
| Div. Yield | 0.57% | KR#1,262/2,405 Sec#77/231 |
| Performance | ||
| 1Y Return | -60.98% | KR#2,151/2,405 Sec#199/231 |
| 1M Return | -16.49% | KR#1,670/2,405 Sec#165/231 |
| From 52W High | -71.50% | KR#2,100/2,405 Sec#178/231 |
| 1Y MDD | -81.92% | KR#2,308/2,405 Sec#212/231 |
| Trading | ||
| Volume | 328,664 shares | KR#239/2,405 Sec#15/231 |
| Trading Value | 2.33B KRW | KR#400/2,405 Sec#35/231 |
| Foreign Own. | 0.77% | KR#2,110/2,405 Sec#207/231 |
| Per Share | ||
| EPS | -75 KRW | KR—/2,405 Sec—/231 |
| BPS | 6,839 KRW | KR#1,273/2,405 Sec#89/231 |
Company Info
Established in 1980 for pharmaceutical manufacturing and sales, the company founded its subsidiary, PharmBay, for specialized pharmaceutical distribution in 2020, which was listed on KOSDAQ in 2025. It specializes in cardiovascular treatments for hypertension and hyperlipidemia, as well as diabetes treatments, handling 126 professional pharmaceutical products. Cardiovascular drugs, diabetes drugs, and CMO business account for 47%, 10%, and 12% of sales, respectively, with the company enhancing competitiveness by expanding its chronic disease treatment lineup. Samik Pharm was founded in 1980 and is headquartered in Bupyeong-gu, Incheon.